Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Special Issue in Honour of the Editor-in-Chief Prof. Dr. Ing. Friedrich Jung on his 70th Birthday
Article type: Research Article
Authors: Arora, N.a; 1 | Caldwell, A.b; c; d; 1 | Wafa, K.b | Szczesniak, A.c | Caldwell, M.c | Al-Banna, N.b | Sharawy, N.b | Islam, S.b | Zhou, J.b | Holbein, B.E.a; e | Kelly, M.E.M.b; c | Lehmann, Ch.a; b; c; d; *
Affiliations: [a] Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada | [b] Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS, Canada | [c] Department of Pharmacology, Dalhousie University, Halifax, NS, Canada | [d] Department of Physiology and Biophysics, Dalhousie University, Halifax, NS, Canada | [e] Chelation Partners Inc, Halifax, NS, Canada
Correspondence: [*] Corresponding author. [*]Dr. Christian Lehmann, MD, PhD, FRCPC, Department of Anesthesia, Pain Management and Perioperative Medicine, QE II Health Sciences Centre, 10 West Victoria, 1276 South Park St., Halifax, NS, B3H 2Y9, Canada. Tel.: +1 902 473 2331; Fax: +1 902 423 9454; E-mail: chlehmann@dal.ca.
Note: [1] First and second author contributed equally to the manuscript.
Abstract: BACKGROUND/OBJECTIVE:Non-infectious uveitis is an inflammatory disease of the eye commonly treated by corticosteroids, though important side effects may result. A main mediator of inflammation are oxygen free radicals generated in iron-dependent pathways. As such, we investigated the efficacy of a novel iron chelator, DIBI, as an anti-inflammatory agent in local and systemic models of endotoxin induced uveitis (EIU). METHODS:Firstly, the effects of DIBI in systemic EIU in Lewis rats were established. 2 hours post intravenous LPS or LPS/DIBI injections, leukocyte activation and functional capillary density (FCD) were examined using intravital microscopy (IVM) of the iridial microcirculation. Secondly, the toxicity of DIBI was evaluated in BALB/C mice for both acute and chronic dosages through gross ocular examination, intraocular pressure measurements and hematoxylin-eosin staining of ocular tissue. Lastly, three groups of BALB/C mice, control, LPS or DIBI + LPS, were studied to evaluate the effectiveness of DIBI in treating local EIU. Five hours post-local intravitreal (i.v) injection, leukocyte activation and capillary density were examined via IVM. RESULTS:Treatment of systemic EIU with DIBI resulted in a reduction of leukocyte activation and FCD improvement within the iridial microcirculation. Toxicity studies suggested that acute and chronic DIBI administration had no adverse effects in the eye. In the local EIU model, DIBI was shown to reduce leukocyte activation and restored the FCD/DCD ratio, providing evidence for its anti-inflammatory properties. CONCLUSIONS:Our study has provided evidence that DIBI has anti-inflammatory effects in experimental uveitis. Additionally, no local ocular toxicity was observed.
Keywords: Iron chelation, ocular inflammation, endotoxin, intravital microscopy, microcirculation
DOI: 10.3233/CH-189109
Journal: Clinical Hemorheology and Microcirculation, vol. 69, no. 1-2, pp. 153-164, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl